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1. Introduction  
The early identification of susceptibility to adverse cardiovascular outcomes and risk 
stratification amongst asymptomatic individuals, as well as amongst those with overt 
disease continues to be one of the major priorities of clinically-orientated research in the 
field of atherothrombosis (Dotsenko et al., 2008). Conventional cardiovascular risk 
assessment is based on traditional risk factors such as serum cholesterol concentrations, 
blood pressure levels, smoking, and diabetes mellitus. However, available data from 
epidemiological studies indicate that these classic risk factors do not fully explain the 
distribution of risk in the general population. On the other hand, classic risk scores may 
provide variable results in different people groups  (Blankenberg et al., 2010). Besides, 
coronary  artery disease often occurs in the absence of traditional risk factors (Yilmaz  et al., 
2007).  Therefore, it is becoming increasingly clear that the newer laboratory  measures may 
be useful to refine risk estimates in the general population. The pressing need for the 
development and clinical implementation of new markers of atherothrombotic disease has 
fuelled rapidly expanding research into cardiac biomarkers  (Dotsenko et al., 2008; Le & 
Wilson, 2010) . 
Cardiovascular biomarkers have the potential to augment clinical risk stratification by 
aiding in screening, diagnosis and assessment of prognosis. However, most current 
biomarkers have only modest predictive value, and there is a need to identify additional 
biomarkers from new biological pathways (May & Wang, 2008). Biomarker research is 
actively developing new testing strategies trying to improve upon current approaches, but it 
is often unclear how to assess the incremental prognostic information that a new test 
provides (Wood & Greenland, 2009).  Some individual biomarkers such as
  
C-reactive 
protein (CRP) have demonstrated consistent associations
 
with incident cardiovascular 
events across multiple studies,
 
but the magnitude of these associations is modest, and only
 
small improvements in discrimination and reclassification are
 
seen. One attractive solution 
to the limitations of individual
 
biomarkers is to combine nonredundant biomarkers into 
panels
 
to enhance risk assessment. However, results of studies testing
 
multiple biomarkers 
for risk prediction in primary prevention
 
populations have not provided a clear picture, 
with some studies
 
showing qualified promise and others suggesting limited
 
value (de 
Lemos & Rohatgi, 2010). This chapter provides an overview
 
of the way of biomarker 
www.intechopen.com
Coronary Angiography 
 – Advances in Noninvasive Imaging Approach for Evaluation of Coronary Artery Disease 
 
268 
discovery and selection for cardiovascular disease (CVD) and the practical considerations 
that are a prerequisite to
 
their clinical use . 
2. What is a biomarker and how do we find the best biomarkers for 
cardiovascular disease?  
Biomarkers are one such tool to better
 
identify high-risk individuals, to diagnose disease 
conditions
 
promptly and accurately, and to effectively prognosticate and 
 
treat patients with 
disease  (Dotsenko et al., 2008). The term biomarker (biological marker) was introduced in 
1989
 
as a Medical Subject Heading (MeSH) term and in 2001, a National Institutes of
 
Health 
(NIH) working group standardized the definition
 
of a biomarker as "a characteristic that is 
objectively measured
 
and evaluated as an indicator of normal biological processes,
 
pathogenic processes, or pharmacologic responses to a therapeutic
 
intervention" (Vasan,  
2006). (Table1).  
Ambiguity concerning decision limits frustrates clinicians and
 
negatively affects the clinical 
adoption of a biomarker. At
 
the time of clinical introduction, a new biomarker ideally 
should
 
have well-characterized decision limits that (a) are pragmatic
 
to apply, (b) have 
undergone validation in multiple studies,
 
(c) have been evaluated in the relevant 
population(s) and application(s),
 
and (d) have achieved synergy between available scientific 
data
 
and regulatory labeling (Morrow & Cook, 2011). 
 
Biological marker (biomarker): A characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacological responses to a therapeutic intervention. 
Risk factor: A risk factor is associated with a disease because it is in the causal pathway 
leading to the disease. 
Risk marker: A risk marker is associated with the disease (statistically) but need not be 
causally linked; it may be a measure of the disease process itself. 
Clinical end point: A characteristic or variable that reflects how a patient feels, functions, 
or survives. 
Intermediate (nonultimate) end point: A true clinical end point (a symptom or measure of 
function, such as symptoms of angina frequency or exercise tolerance) but not the ultimate 
end point of the disease, such as survival or the rate of other serious and irreversible 
morbid events. 
Validation of a biomarker (assay or method validation): A process for assessing 
performance characteristics (ie, sensitivity, specificity, and reproducibility) of a biomarker 
measurement or an assay technique. 
Qualification of a biomarker (clinical validation): The evidentiary process linking a 
biomarker to disease biology or clinical outcome. 
Evaluation of a biomarker: A process of linking biomarkers to outcomes, often with a 
view to establish surrogate status. 
Adapted from Reference : Vasan, (2006). 
Table 1. Biomarkers: A basic glossary. 
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How do we find the best biomarkers for cardiovascular disease?  Cardiovascular risk 
estimation by novel biomarkers needs assessment in disease-free population cohorts, 
followed up for incident cardiovascular events, assaying the serum and plasma archived at 
baseline (Blankenberg et al., 2010). Composite end points are often used to increase the 
number of events in the comparison with persons who do not develop events. Such 
composite end points might include the development of acute coronary syndrome , cardiac 
failure, cerebrovascular disease, and intermittent claudication. When possible, it is probably 
best to focus the research  interest  on discrete events, such as the occurrence of a first 
coronary heart disease event (Le & Wilson, 2010); or perhaps research should be done 
considering the severity of the disease, namely the degree of coronary  stenosis evaluated by 
coronary  angiography.  Besides, diagnosing coronary artery disease (CAD) in  patients at 
risk can be challenging and typically requires coronary  angiography  as the gold standard 
(Rosenberg  et al, 2010).  
When a new biomarker X is evaluated, it is important to remember
 
that the question of 
interest is not whether X is a better predictor
 
of disease than a previously known biomarker 
Y. Rather, the
 
pertinent question is whether X improves the predictive accuracy
 
of the best 
available model (representing the standard of care
 
for that disease) that incorporates several 
known predictors
 
of disease including Y. Thus, the relative added values of
 
new biomarkers 
is best evaluated by estimating the increment
 
to the c statistic compared with that from a 
model that incorporates
 
other previously known predictors (Vasan,  2006). The c statistic, or 
area under the receiver operating characteristic (ROC) curve, achieved popularity in 
diagnostic testing, in which the test characteristics of sensitivity and specificity are relevant 
to discriminating diseased versus nondiseased patients (Cook, 2007). 
Although it is generally believed that new biomarkers should
 
add to the c statistic to be 
useful, there are exceptions to
 
this rule. Novel biomarkers (eg, homocysteine) that are not
 
incremental to known risk factors may be measured in select
 
clinical situations such as in 
the following: asymptomatic
 
individuals without obviously elevated conventional risk 
factors
 
but with very strong family history of vascular disease; patients
 
with premature 
vascular disease but no obvious risk factors;
 
and patients with aggressive recurrent vascular 
disease in the
 
face of well-controlled levels of conventional risk factors  (Vasan,  2006). 
Most of the cardiovascular biomarker studies that test the  utility of a large number of 
laboratory tests are hypothesis-generating in nature, and validation of the results is 
important. Several validations of a new biomarker may be needed to demonstrate that the 
new test provides information that could help predict risk in the population or in specific 
subgroups of the population . When the usefulness of a new test for predicting disease is 
assessed, it is important to bear in mind whether the test adds or replaces information 
concerning risk or prognosis for a specific clinical or subclinical outcome.The test must also 
be reproducible, be standardized, have a high diagnostic sensitivity and specificity, and 
have a high predictive value (Le & Wilson, 2010). 
3. What are the new biomarkers for CVD?  
In recent years, a number of new candidate risk factors or markers have been proposed as 
significant predictors of atherosclerosis and its complications (Table 2) (Hackam & Anand,  
2003). In a contemporary publication of the MONICA (Monitoring of Trends and 
Determinants of Cardiovascular Disease) investigators, Blankenberg and colleagues 
evaluated the potential contribution  of 30 novel biomarkers to the 10-year cardiovascular 
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disease risk in 2 population cohorts (Blankenberg et al., 2010). These biomarkers were part 
of the MORGAM (MONICA, Risk, Genetics, Archiving, and Monograph) Biomarker Project 
(Evans et al.,2005) and were representative of 9 distinct metabolic processes linked to 
atherosclerosis . They  include (a) lipid-related  biomarkers, (b) renal function markers, (c) 
metabolic markers representing glucose and obesity pathways, (d) markers of vascular 
function and neurohumoral activity, (e) inflammation markers, (f) markers of oxidative 
stress and antioxidants, (g) coagulation markers, (h) angiogenesis markers, and (i) necrosis 
markers ; classified similar to the risk factors in Table 2 (Blankenberg et al., 2010). 
In recent years, the importance of inflammation and increased reactive oxygen species (ROS) 
for the pathogenesis of atherosclerosis is well recognized (Kaneto et al, 2010; Mayer, 2000; 
Tabit et al, 2010). Consequently, “non-traditional factors” such as high-sensitive C-reactive 
protein (hs-CRP), total homocysteine (t-Hcy), as well as oxidative stress, have been 
proposed as risk factors for the development and progression of atherosclerosis and 
atherothrombotic cardiovascular disease (Djoussé et al,2001; Eren et al,2002; Lee  et al,2003; 
Pence et al, 2003). Therefore, this chapter will focus on total-homocystein,  hs-CRP and the 
underlying oxidative stress mechanism of CVD or atherosclerosis.  
 
Inflammatory Markers Lipid-Related Factors 
C-reactive protein 
Interleukins (eg, IL-6) 
Serum amyloid A 
Vascular and cellular adhesion molecules 
Soluble CD40 ligand 
Leukocyte count 
Small dense low-density lipoprotein (LDL) 
Lipoprotein(a) 
Remnant lipoproteins 
Apolipoproteins A1 and B 
High-density lipoprotein subtypes 
Oxidized LDL 
Hemostasis/Thrombosis Markers Other Factors 
Fibrinogen 
von Willebrand factor antigen 
Plasminogen activator inhibitor 1 (PAI-1) 
Tissue-plasminogen activator 
Factors V, VII, and VIII 
D-dimer 
Fibrinopeptide A 
Prothrombin fragment 1+2 
Homocysteine 
Lipoprotein-associated phospholipase A(2) 
Microalbuminuria 
Insulin resistance 
PAI-1 genotype 
Angiotensin-converting enzyme genotype 
ApoE genotype 
Infectious agents: Cytomegalovirus, 
Chlamydia pneumonia, Helicobacter pylori, 
Herpes simplex virus 
Psychosocial factors 
Platelet-Related Factors 
Platelet aggregation 
Platelet activity 
Platelet size and volume 
 
Table 2. Novel risk factors for atherosclerotic vascular disease (Hackam & Anand,  2003). 
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4. Diagnostic values of homocysteine, C-reactive protein and bilirubin for 
coronary artery disease.   
C-reactive protein (CRP) is a circulating acute-phase reactant that is increased many-fold 
during the inflammatory response to tissue injury or infection (Pepys & Baltz, 1983). This 
protein has received substantial attention in recent years as a promising biological predictor 
of atherosclerotic disease (Pearson et al., 2003). On the other hand, it has been postulated 
that mild to moderate elevations of homocysteine in the general population predispose to 
atherosclerosis in a manner akin to the classic risk factors (Hackam & Anand,  2003). 
Additionally, the adaptive and protective responses of arterial vasculature against oxidative 
stress are  important in the prevention of atherosclerosis (Hoekstra et al, 2004). 
4.1 CRP or hs-CRP 
An evolving body of work suggests that even small increases  in CRP within the normal 
range are predictive of future vascular events in apparently healthy, asymptomatic 
individuals (Ridker et al, 2002).  Danesh et al reported a meta-analysis of 14 prospective 
long-term studies of CRP and the risk of nonfatal myocardial infarction or death from 
coronary heart disease (Danesh et al., 2000). The attention in this protein stems in part from 
a recent shift in thinking about the pathogenesis of CVD, an entity once  primarily 
considered to be a bland lipid storage disease. Inflammation is now widely accepted as 
central to every aspect of the atherosclerotic process, from its initiation to its progression to 
plaque rupture, the latter being the essential event underlying the acute coronary 
syndromes  (Hackam & Anand,  2003). Debate exists about the utility of CRP as a marker of 
cardiovascular risk, given its role as an acute-phase reactant and hence its elevation in the 
presence of any inflammatory focus or injury. This has been countered somewhat by the 
development in recent times of an ultrasensitive assay, which has been shown to have a 
degree of measurement stability similar to that of total cholesterol (Davison & Davis, 2003). 
In other words, the guidelines identify CRP (as measured by a high-sensitivity [hs] assay--
hence the name hs-CRP) as the inflammatory marker of choice for cardiovascular risk 
stratification. Although a number of other inflammatory markers such as serum amyloid A, 
white blood cell count, and fibrinogen have been investigated, the “hs-CRP” level has the 
most stability, assay precision, accuracy, and availability (Shishehbor et al, 2003). 
4.2 Homocysteine 
Interest in homocysteine as a causal factor was spurred by the observation that more than 
50% of children with the genetic disorder homocystinuria die of premature vascular disease 
and strategies that reduce homocysteine levels in these children have been shown to 
decrease  vascular event rates (Humphrey  et al, 2008).  Mechanistic studies have 
demonstrated that homocysteine  might induce vascular damage by promoting platelet 
activation, oxidative stress, endothelial dysfunction, hypercoagulability, vascular smooth 
muscle cell proliferation, and endoplasmic reticulum stress (De Bree et al., 2002;  Mangoni & 
Jackson, 2002). In their meta-analysis, Humphrey et al evaluated homocysteine levels as a 
predictor of new CAD events in persons without known CAD. Their review showed an 
association between elevated homocysteine levels and CAD that was independent of 
Framingham risk factors. In the overall analysis, the risk of any CAD event increased 
approximately 20% for each increase of 5 μmol/L of homocysteine. Consequently, elevated 
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homocysteine levels independently and moderately increased the risk of developing CAD 
either in a causal manner or as a risk marker by approximately 20% (Humphrey  et al, 2008). 
4.3 Oxidative stress and bilirubin 
Imbalances in the redox status in which excess oxidation occurs or reducing power cannot 
be maintained (e.g. in inflammation, age, smoking, high lipid content and oxidation) creates 
a state  in which molecular and tissue modifications progress rapidly, leading to 
development of lesions and full-blown atherogenesis. Oxidative stress  does  not replace the 
recognized role of lipids and cholesterol in atherosclerosis, but rather underline that role. 
Indeed, quantifying redox processes may well elucidate some molecular mechanisms by 
which lipids mediate atherogenesis (Gamkrelidze et al., 2008). Bilirubin has been considered 
an antioxidant, with capacity to remove reactive species of oxygen. Recent data advocates 
the idea that an increased bilirubin level promotes protection against atherosclerosis  (Ghem 
et al., 2010). 
The heme oxygenase responsible for the degradation of heme grouping of hemoglobin is a 
stress  inducible enzyme with antioxidative properties . The products of its reaction 
(bilirubine, carbon monoxide and iron) develop a potential protective role against 
atherosclerosis (Hoekstra et al, 2004). Studies have suggested that different circulating forms 
of bilirubin have the capacity to remove  a variety of reactive species of oxygen, and inhibit 
the oxidation of LDL particles and the chemotaxis of monocytes, all of which are crucial 
steps in atherogenesis (Ghem et al., 2010). 
In a study we have  done , we assessed the diagnostic performance and relationship of 
bilirubin with hs-CRP and t-Hcy  for cardiovascular disease in men and women in an 
angiographically documented design. The study demonstrated that patients with 
angiographically confirmed coronary artery disease (CAD) had significantly higher serum 
hs-CRP and t-Hcy levels than non-stenotic patients (patients with normal angiogram) and 
the apparently healthy control group.Optimal cut-off levels and the associated diagnostic 
performances (sensitivity, specificity and diagnostic value) of serum bilirubin, hs-CRP, t-
Hcy, based on ROC analysis, are given in Table3. Optimal cut-off levels for bilirubin, hs-
CRP and t-Hcy providing the maximum efficiency found in patients (n = 319) with CAD 
were 0.59 mg/dL, 1.09 mg/dL and 12.1 µmol/L respectively. 
 
Variable Cut-off level
Sensitivity
(%) 
Specificity
(%) 
Diagnostic 
value (area 
under the 
curve) 
+LR -LR 
Bilirubin 0.59 mg/dL 70.9 40.4 0.507 1.19 0.72 
High-sensitivity 
C-reactive protein 
      
1.09 mg/dL 50.0 80.7 0.648 2.59 0.62 
Total homocysteine 121 ^mol/L 76.8 70.2 0.781 2.67 0.29 
+LR = positive likelihood ratio 
-LR = negative likelihood ratio 
Table 3. Optimal cut-off levels and associated specificity, sensitivity and diagnostic value of 
concentrations of biomarkers for the diagnosis of angiographically documented coronary 
artery disease 
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These data strongly suggest that serum t-Hcy helps to identify individuals at risk of 
atherosclerosis (AUC value 0.781), especially among those with elevated hs-CRP and 
decreased bilirubin levels. t-Hcy showed the highest AUC value (0.781) compared to hs-CRP 
(0.648) and bilirubin (0.507). Area under the curve (AUC) values in receiving operating 
characteristics (ROC) curve (as a measure of discriminating efficacy) were used for 
comparison of the diagnostic values of different analyses (including only the CAD and non-
CAD groups, using angiography as the gold standard). ROC curve-based sensitivities of 
bilirubin, hs-CRP and t-Hcy levels were 70.9%, 50.0%, 76.8% respectively. The specificities of 
bilirubin, hs-CRP and t-Hcy were 40.4%, 80.7% and 70.2% respectively (data of ROC curves 
are shown in Figures 1–3). 
 
 
Specificity 
Fig. 1. ROC curve for total homocysteine. 
 
 
Specificity 
Fig. 2. ROC curve for hs-CRP. 
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Specificity 
Fig. 3. ROC curve for bilirubin. 
In agreement with previous reports, we found that the bilirubin levels in serum were 
significantly lower in the patients with CAD than in age- and sex-matched controls 
(Madhavan  et al., 1997; Schwertner  et al., 1994;  Vitek et al., 2002).  We found that a serum 
bilirubin concentration of 10.0 µmol/L (0.58 mg/dL) discriminated between high and low 
cardiovascular risks . 
Additionally, we found that the number of stenotic coronary arteries was significantly 
associated with elevated serum t-Hcy and hs-CRP concentrations. Several researchers have 
investigated the risk of myocardial infection in individuals with the UGT1A1*28 allele ( 
Bosma et al., 2003; Schwertner, 2003).  According to the “oxidative modification hypothesis”, 
which suggests atherogenesis is initiated by oxidization of low-density lipoprotein particles, 
it has been suggested that increased physiological concentrations of serum bilirubin may 
reduce atherogenic risk by reducing oxidation. An involvement of bilirubin in immune 
reactions and inflammatory processes has also been documented (Delores  et al., 2000; 
Kronenberg  et al., 2002; Lin et al., 2003).  
Earlier studies have reported differences in the levels of t-Hcy, ranging between 13.9–20.1 
µmol/L in persons with CAD (Yu et al., 2000; Zylberstein et al., 2004). We found a mean t-Hcy 
level of 19.4 (SD 8.73) µmol/L in the CAD group, 10.7 (SD 5.14) µmol/L in the healthy group 
and 13.0 (SD 8.61) µmol/L in the non-CAD group. Some differences between reported serum 
t-Hcy levels may be related to analytical methods and ethnic differences. A study in 19 centres 
in Europe reported high homocysteine levels and increased risk of CAD in smokers  (Graham  
et al., 1997). We found that the t-Hcy levels tended to increase in the presence of more 
cardiovascular risk factors, i.e. male gender, older age, diabetes mellitus, hyperlipidaemia and 
certain chronic diseases. As expected, traditional coronary risk factors were more prevalent 
among those participants with elevated levels of t-Hcy and hs-CRP in our study, as in other 
studies  (Abdemouttaleb  et al., 2000; Sesso  et al., 2003; Siri  et al., 1998).    
5. What is new about hyperhomocysteinemia?  
Homocysteine is an accepted independent risk factor for several major pathologies 
including cardiovascular disease, birth defects, osteoporosis, Alzheimer’s disease, and renal 
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failure. Interestingly, many of the pathologies associated with homocysteine are also linked 
to oxidative stress (Suszynska et al., 2010). Evidence indicates that hyperhomocysteinemia, 
which occurs in 5–7% of the general population is a risk factor for CVD, but how? 
(Jakubowski, 2004). Hyperhomocysteinemia is accused of being responsible for elevating 
oxidative stress as a result of formation of Hcy- thiolactone or Hcy-thiyl radical, which may 
lead to impairment of cell signaling and cause pathology (Doshi et al., 2001; Lang et al., 
2000). Many researchers, and especially Jakubowski, suggested that metabolic conversion of  
Hcy to Hcy-thiolactone followed by subsequent spontaneous protein N-homocysteinylation 
by Hcy-thiolactone might contribute to Hcy toxicity in humans. (Jakubowski, 2002). Hcy-
thiolactone is a reactive intermediate that causes protein N-homocysteinylation through the 
formation of amide bonds with ɛ-amino groups of protein lysine residues; in the event,  
homocysteinylated proteins  may lose their biological activities (Jakubowski, 2003). 
Whereas epidemiological data indicate that elevation of plasma homocysteine is not 
associated with a significant change in plasma total cholesterol, some studies have reported 
a negative correlation with HDL concentrations  (Ciaccio & Bellia, 2010; Domagała  et al., 
2006; Williams  & Schalinske, 2010). Because low plasma HDL concentration sometimes is 
associated with increased risk of  CVD, whereas other conditions with low plasma HDL 
concentration are associated with improved prognosis, it seems that it is not only the 
concentration per se but also the function of the HDL particles that is important for its 
antiatherogenic effects (Bełtowski, 2005; Mikael et al.,2006).  HDL particles are susceptible to 
structural modifications mediated by various mechanisms, including oxidation, glycation, 
or enzymatic degradation, affecting their functional properties .Moreover, in vitro studies 
have shown that homocysteinylation of HDL may reduce the activity of the enzyme 
Paraoxonase (PON), which is associated with human HDL, thus rendering the HDL particle 
more susceptible to oxidative damage.  Formation of inflammatory HDL has been suggested 
to correlate with decreases  in the activities of various HDL associated enzymes, such as 
PON, a multifunctional enzyme with antioxidant capacity, and the ability to detoxify the 
homocysteine metabolite homocysteine thiolactone  (Bełtowski, 2005; Liao  et al., 2007)  . 
Paraoxonase is thought to influence serum homocysteine concentrations, at least in part, due 
to its homocysteine thiolactonase activity and to play a role in atherosclerosis. (Yang  et al, 
2006).  Hcy- thiolactonase activity is influenced by both PON1 and MTHFR genotypes and 
there is a direct relation between Hcy and Hcy- thiolactone levels. In relation to this matter, 
Jakubowski et al. hypothesized that high thiolactonase associated PON1  R and L alleles 
should confer significant cardiovascular protection in subjects with high Hcy levels  
(Jakubowski et al., 2001). 
6. Conclusion  
The availability of well-validated decision limits is vital to optimal integration of a new 
biomarker into clinical practice. Approaches to internal validation and data-mining methods 
lead to overfitting and overestimation of risk relationships and are generally not sufficient 
for selecting final clinical cutpoints. Such methods, when applied correctly, can be 
reasonable for suggesting cutpoints for external validation. Biomarkers that have monotonic 
linear relationships with risk are best handled as continuous variables when incorporated 
into comprehensive risk models. As consistently demonstrated in clinical practice and 
professional society guidelines, however, practitioners will almost always seek thresholds to 
provide structure for clinical decision-making, such as those existing for cholesterol. 
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Therefore, such cutpoints warrant development and validation. Although the approach is 
demanding, we recommend assessment of clinical decision limits by external validation in 2 
or more data sets that are appropriate to each of the proposed clinical application(s), with 
attention paid to the possibility of differences in risk relationships in clinically relevant 
subpopulations (Morrow & Cook, 2011). 
To conclude, there is little evidence of an association between the serum concentration of 
bilirubin and atherosclerosis. In contrast, the concentration of novel (t-Hcy and hs-CRP) and 
traditional risk markers may be stronger markers for atherosclerosis in CAD patients. 
Additional studies are still necessary to confirm and demonstrate the association of these 
findings with clinical outcomes. 
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